CANNABIDIVARIN (CBDV): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Cannabidivarin is a chemical in the cannabis plant. It is similar in structure to cannabidiol (CBD). Like CBD, cannabidivarin does not affect thinking. Cannabidivarin is approved for use as a medicine in Europe for treating two rare conditions. It's not approved for use as a medicine in the U.S. or Canada.

Cannabidivarin is used for seizure disorder, nausea, long-term swelling (inflammation) in the digestive tract, and other conditions, but there is no good scientific evidence to support these uses.

How does it work ?

Cannabidivarin seems to make certain nerve cells less active. These nerve cells are involved in swelling (inflammation), seizures, pain, and other conditions. By making these cells less active, cannabidivarin might improve these conditions.

Uses & Effectiveness ?

Possibly Ineffective for

Seizure disorder (epilepsy). Taking cannabidivarin for 2 weeks doesn't appear to reduce seizures in people with poorly controlled seizure disorder.

Insufficient Evidence for

Rett syndrome.
Fragile X syndrome.
Autism.
A rare, inherited disorder that causes obesity, short stature, and learning disability (Prader-Willi syndrome or PWS).
A type of inflammatory bowel disease (ulcerative colitis).
A type of inflammatory bowel disease (Crohn disease).
HIV/AIDS.
Multiple sclerosis (MS).
Nausea.
Duchenne muscular dystrophy.
Other conditions.

More evidence is needed to rate the effectiveness of cannabidivarin for these uses.

Side Effects

When taken by mouth: There isn't enough reliable information to know if cannabidivarin is safe. It might cause side effects such as diarrhea, dizziness, and nausea.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if cannabidivarin is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use

Interactions ?

We currently have no information for CANNABIDIVARIN (CBDV) Interactions.

Dosing

The appropriate dose of cannabidivarin depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for cannabidivarin. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

Clinical Trial Results: A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures. European Medicines Agency: EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002594-11/results. Accessed December 16, 2019.

Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73. View abstract.

European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf. Accessed December 16, 2019.

European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-cannabidivarin-treatment-fragile-x-syndrome_en.pdf. Accessed December 16, 2019.

Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131-41. View abstract.

Iannotti FA, Pagano E, Moriello AS, et al. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol. 2019;176(10):1568-1584. View abstract.

Pagano E, Romano B, Iannotti FA, et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacol Res. 2019;149:104464. View abstract.

Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8. View abstract.

Russo C, Ferk F, Misík M, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):179-188. View abstract.

Vigli D, Cosentino L, Raggi C, Laviola G, Woolley-Roberts M, De Filippis B. Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology. 2018;140:121-129. View abstract.

Zamberletti E, Gabaglio M, Piscitelli F, et al. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. J Psychopharmacol. 2019;33(7):894-907. View abstract.

Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Front Cell Neurosci. 2019;13:367. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2018.

VITAMINS & SUPPLEMENTS CENTER

DRUGS AND MEDICATIONS CENTER

FIRST AID RESOURCES

RELATED TO VITAMINS & SUPPLEMENTS

CANNABIDIVARIN (CBDV)